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ABSTRACT
Major depressive disorder (MDD) is a neuropsychiatric condition that is becoming
increasingly prevalent in our country. According to Cai, Huang, and Hao (2015), MDD is
“common and devastating” (p. 61) and has a very complex pathophysiology. Until recently, a
definitive etiology had not been found, however, new evidence has suggested that Brain-derived
neurotrophic factor (BDNF) and cognitive-emotional biomarkers may be a key into the
mechanism of this disorder.
My literature review of articles found in PubMed, CINAHL, Cochrane Library, and
PsychINFO within the last ten years focused on the hypotheses of the pathophysiology of MDD,
cognitive-emotional biomarkers, and BDNF. The review found that MDD has a multitude of
interconnecting systems that highlight its mechanism, and this is why it is so difficult to find a
treatment option that works. However, cognitive-emotional biomarkers were able to predict the
efficacy of certain antidepressants in the treatment of MDD. BDNF was also found to be
decreased in patients with MDD and increased after treatment with certain medications. These
systems may help predict better treatment response and an overall improvement of the burden of
this disease.

Key Terms: brain-derived neurotrophic factor, sertraline, venlafaxine, venlafaxine
hydrochloride, depressive disorder, serotonin and noradrenaline reuptake inhibitors, and
serotonin uptake inhibitors
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INTRODUCTION
MDD, according to Cai et al. (2015), “is a mental disorder characterized by prominent
and persistent low mood, mental retardation, cognitive impairment, volitional decline, and
somatic symptoms” (p.61). The Centers for Disease Control and Prevention (2016) states that
almost 10% of adults aged 40-59, and more than 1 out of 20 Americans 12 years of age and older
reported current depression. Up until this point, there has not been a clear etiology of this
disorder. In the last decade, there has been an abundance of research showing that levels of
neurotrophins, such as BDNF in the brain, may be involved in the pathophysiology of MDD and
may accurately predict the efficacy of antidepressant medications and the remission of
depression. The purpose of this review is to determine how BDNF and cognitive-emotional
biomarkers factor into the pathophysiology of MDD, and if they can accurately predict the
efficacy and outcome of certain antidepressants.
STATEMENT OF PROBLEM
According to Cai et al. (2015), “MDD can reduce the capacity of a patient to study, work,
and engage in social skills” (p.61). It can also increase the risk of suicide and disability rate and
has a very high recurrence rate. According to the World Health Organization, there were 300
million patients with MDD in 2015. “It is estimated that by 2020, the disease burden caused by
MDD will be ranked next to ischemic heart disease, becoming the second most common cause of
disability and death” (Cai, 2015, p.61). The etiology of MDD has not been completely
understood, according to Ristevska-Dimitrovska et al. (2013), and many new hypotheses in the
pathophysiology of MDD have been formulated. Not having a definitive mechanism by which
this disease works makes it harder to find treatment options that are going to provide the efficacy
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and tolerability that these patients need. As more definitive mechanisms are discovered,
treatment options can be more effective as they are tailored to the specific mechanism.
RESEARCH QUESTIONS
In adults with MDD, does BDNF play a role in the pathophysiology of MDD?

In treatment of adults with MDD, do cognitive biomarkers predict the efficacy and
outcome of treatment and remission?

In treatment of adults with MDD, does BDNF predict the efficacy and outcome of
treatment and remission?
METHODOLOGY
For my scholarly project, I utilized PubMed, CINAHL, Cochrane Library, and
PsychINFO to collect pertinent information regarding cognitive markers and BDNF and their
affiliation with depression. Within these databases, I used the following search terms: brainderived neurotrophic factor, sertraline, venlafaxine, venlafaxine hydrochloride, depressive
disorder, serotonin and noradrenaline reuptake inhibitors, and serotonin uptake inhibitors, in
various combinations, to generate research. In PubMed, CINAHL, and PsychINFO, MeSH terms
were used. I focused on peer-reviewed articles, including studies and reviews that were
published within the last 10 years.
LITERATURE REVIEW
A review of the literature showed that BDNF is reduced in patients with MDD. It has also
been shown to increase in response to certain antidepressants. Cognitive and emotional
biomarkers were also shown to increase the efficacy of antidepressant treatments. The primary
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goal of treatment for MDD is to reach remission, which Kurita, Nishino, Kato, Numata, and Sato
(2012), defined “as the absence of significant signs or symptoms” (p.1). These neuronal
biomarkers may be the key to improving remission rates upon patients with MDD, and to finally
be closer to a definitive cure of this disease.
Pathophysiology of Major Depressive Disorder (MDD)
MDD is diagnostically classified under The Diagnostic and Statistical Manual of Mental
Disorders. It states that “MDD presents with at least 5 of the following 9 symptoms: depressed
mood or anhedonia (patient must have at least 1; present most of the day nearly every day for a
minimum of 2 consecutive weeks), sleep disturbance, change in appetite or weight, psychomotor
problems, lack of energy, poor concentration, feelings of worthlessness or guilt, and suicidal
ideation.” The symptoms need to “cause clinically significant distress or impairment in social,
work, or other areas of functioning”, and the episode cannot be “attributable to the physiologic
effects of a substance or other medical disorder” (ClinicalKey, 2017).
According to Cai et al. (2015), the understanding of the pathophysiology of Major
Depressive Disorder has, up to this point, been mainly based on the monoamine-deficiency
hypothesis. This hypothesis “proposes that the occurrence of depression is associated with
deficiencies of three major monoamine transmitters, 5-hydroxytryptamine (5-HT),
norepinephrine (NE), and dopamine (DA)” (p.61). However, this hypothesis has been seriously
challenged in the last few years for a couple of reasons. Antidepressant treatment only has an
efficacy of 60-65%, a remission rate of only 30%, and a high percentage of patients that do not
show any improvement. Also, antidepressants increase the levels of these monoamine
neurotransmitters in the central nervous system (CNS), but it often takes at least two weeks for
them to take effect. This evidence suggests that the monoamine deficiency only partly explains
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the pathogenesis of depression. This review performed by Cai et al. looks at the new hypotheses
that have emerged and offers new thinking in the mechanism behind depression.
Neurotrophic factors are a class of small proteins that include nerve growth factor,
BDNF, insulin-like growth factor, and transfer growth factor. Some of the roles of these proteins
include “maintaining neural survival in embryonic development and promoting differentiation,
facilitating axonal growth, guiding nerve-growth direction, maintaining the survival of mature
neurons, and accelerating neurogenesis” (Cai, 2015, p.62). Patients with depression may show
atrophy or lack of neurons, most commonly in the hippocampus and cerebral cortex of the brain.
Other hypotheses in the pathophysiology of depression included inflammatory cytokines,
the hypothalamus-pituitary-adrenal (HPA) axis, and glutamate receptors. Verduijn et al. (2015)
also found that dysregulation of vitamin D may be integrated into the etiology of MDD. Cai et al.
(2015) believed that BDNF dysfunction and increased apoptosis are the final common cascades
in the pathogenesis of MDD and new therapeutic strategies to enhance BDNF may be an
effective action against this disorder.
Rot, Mathew, and Charney (2009) aimed to review data on “how genes, psychosocial
adversity in childhood, and ongoing or recent psychosocial stress may impact multiple
neurobiological systems relevant to major depressive disorder” (p.305). Rot et al. stated that
investigations have traditionally been focused on the monoamine neurotransmitters serotonin and
norepinephrine in the pathophysiology of depression. This hypothesis initially postulated that
“depressed individuals are likely to have low levels of these neurotransmitters” (p.305), and
various antidepressant medication will acutely increase their levels. However, they do not exert
their clinical benefit immediately, and for some people do not offer any benefit at all. This
suggests that there must be another variable behind the failure of these medications.
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Rot et al. (2009) stated that there has not been a specific gene or series of genes found
that cause depression, rather, variations in genes, or polymorphisms, may increase the risk of
depression. “Genes help control the metabolism of neurotransmitters and their receptors, the
numbers of particular types of neurons and their synaptic connections, the intracellular
transduction of neuronal signals, and the speed with which all of these can change in response to
environmental stressors” (Rot, 2009, p.306). A variation of these genes could cause detrimental
effects and is why genetic testing in relation to depression has recently become more popular.
Brain-derived neurotrophic factor “plays a major role in the birth, survival, and
maturation of brain cells during development” and “is important for cell growth and for allowing
changes in the synapses between neurons (synaptic plasticity) throughout life” (Rot, 2009,
p.307). A polymorphism of this growth factor affects the intracellular transport and secretion of
BDNF and may increase depression vulnerability. There has also been further evidence from
postmortem studies, in which low levels of BDNF have been found in the hippocampus and
prefrontal cortex of symptomatic depression patients, as was reported with Cai et al. (2015).
Rot et al. (2009) identified an important downside of many studies on the
pathophysiology of depression, in which they tend to focus more on people who are currently
depressed. This gives readers a lot of information, however, the data does “not allow for a
distinction to be made between cause and effect” (p.305). For example, is the reduction in
serotonin synthesis causing depression, or does depression cause a reduction in serotonin
synthesis? Is a third factor responsible for both?
It is clear that there is a multitude of interconnected systems that are involved in the
pathophysiology of major depressive disorder. This explains why antidepressant treatment
frequently does not lead to clinical remission, as most target monoamines. “The exact roles of
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the monoamine and other neurotransmitter systems as well as their extracellular, intracellular,
local, and regional targets” (Rot, 2009, p.311) of this disorder are continuing to be defined, and a
clearer etiology underlying this disorder would help warrant more successful treatment.
Cognitive & Emotional Biomarkers
According to Castellano et al. (2016), it has been shown that MDD is often associated
with cognitive dysfunction involving “attention, learning, memory, and executive functioning”
(p.1291) and the presence of these cognitive symptoms may predict a decreased response rate to
antidepressant medications. Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin and
Noradrenaline Reuptake Inhibitors (SNRIs) have shown efficacy for affective symptoms (mood,
emotions, or feelings), however, it is unclear if they improve cognitive symptoms. In this
prospective, observational, multicenter cohort study, Castellano et al. aimed “to test the
hypothesis that SSRIs and/or SNRIs may affect cognitive symptoms in MDD patients and, if so,
to evaluate whether or not such an effect is correlated to their effect on affective symptoms”
(p.1291).
The 52 MDD patients (mean age 54.7 ± 12.1 years; 39 women and 13 men) involved in
the study were recurrent depressive patients and were having an acute depressive episode at the
beginning of the study and a recent history (in the last 4 weeks) of having partial response to a
previous antidepressant drug. A total of 33 patients (2 left the study due to adverse effects) were
assigned to 12-week treatment with an SSRI, including escitalopram (n=14), paroxetine (n=9),
sertraline (n=1), and citalopram (n=9). The remaining 16 patients (1 left the study due to adverse
effects) were assigned to SNRI treatment with either venlafaxine (n=8) or duloxetine (n=8). The
patients underwent cognitive and neuropsychiatric assessments before the switch of
pharmacological treatment, and at 4 and 12 weeks of follow-up. The following psychometric
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instruments were used to assess cognitive and affective symptoms: Hamilton Depression rating
scale (HDRS) and Beck Depression Inventory (BDI-II) to assess symptoms, and Mini Mental
State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Frontal Assessment
Battery (FAB), Rey’s 15 Words Test, and Digit Span to assess cognitive function.
Castellano et al. (2016) found that both SSRIs and SNRIs reduced the affective
symptoms in MDD patients at the end of the 12-week treatment (HDRS score 22.18 ± 7.38 to
12.94 ± 7.93 in the SSRI cohort and HDRS score 18.94 ± 4.58 to 12.55 ± 8.99 in the SNRI
cohort) (BDI-II score from 33.67 ± 11.67 to 20.06 ± 12.78 and from 30.06 ± 8.97 to 20.06 ±
12.39 in the SSRI and SNRI cohort, respectively), as well as significantly improved the global
cognitive function (increased scores of both MMSE and MoCA). Both SSRIs and SNRIs
improved executive function (FAB scores) and verbal memory (Rey’s 15 Words Test), however,
this improvement was independent from the efficacy of affective symptoms.
Castellano et al. (2016) reported that “a recent study demonstrated that a significant
proportion (over 20%) of MDD patients successfully treated with SSRIs for over 6 months
reported cognitive symptoms including inattentiveness, lack of concentration, and memory
impairment. Therefore, long-term treatment studies with SSRIs and/or SNRIs are needed to
assess whether and how these drugs can differentially affect verbal and working memory in
MDD patients” (p.1296). Other limitations of this study included the length of time of treatment,
as well as the small sample size. Longer observational studies are needed to better understand
how these drugs can differentially affect cognitive symptoms in MDD.
According to Etkin et al. (2015) there are a wide range of treatment options for patients
with MDD, however, “only approximately one-third of patients reach remission with any single
antidepressant” (p.1332). In comparison with Castellano et al. (2016), Etkin et al. stated that
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“depression is characterized by perturbations in psychomotor response speed, processing speed,
executive functions (eg, attention and working memory), memory encoding, and recall and
emotion processing” (p.1332). Etkin et al. performed an analysis on a previous study, termed the
iSPOT-D (International Study to Predict Optimized Treatment in Depression) trial. His report,
which analyzed data based on a cross-validated multi-variate pattern, assesses whether
performance of standardized tests of cognition and emotional capacities predicted remission or
response of depressive symptoms.
The iSPOT-D study included 1,008 adults with first-onset or recurrent MDD, as well as
336 healthy controls that were matched in age, gender, and years of education. The participants
were randomized to receive escitalopram, sertraline, or venlafaxine-extended release. Study
visits occurred at week 0 (pretreatment) and week 8. At these visits, clinician raters completed
the Hamilton Rating Scale for Depression (HRSD) and participants completed the 16-item Quick
Inventory of Depressive Symptomatology-Self Report (QIDS-SR). For this report, Etkin et al.
(2015) defined remission as “either an HRSD score ≤7 or a QIDS-SR score ≤5” (p.1333).
Response was defined as “≥50% decrease from baseline in either the HRSD or QIDS-SR score”
(p.1333). At baseline, participants also completed a battery of standardized tests to evaluate the
range of cognitive and emotional capacities.
Etkin et al. (2015) focused his analyses on patients (n=655) that completed the iSPOT-D
trial (taking the randomized medication and having clinical scores at baseline and week 8).
Observations showed that “remission rates with escitalopram treatment were higher for
individuals predicted to remit with escitalopram (58%) than for those predicted to not remit
(16%)” (Etkin, 2015, p.1336), and remission rates were higher if they received escitalopram
versus sertraline or venlafaxine (58% vs. 32%, p=0.016). Etkin et al. stated participants that were
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predicted to reach remission had slightly lower depressive severity, were more educated, and
received a lower dose of escitalopram at week 8. The patients that were predicted not to reach
remission had generally impaired cognitive functioning. Those predicted to not remit with
escitalopram remitted at a lower rate if they received escitalopram compared with venlafaxine
and sertraline (16% vs. 26%, p=0.300).
According to Gyruk et al. (2016), cognitive function and related constructs are defined as
“psychological processes that underlie the ability to carry out goal-directed behaviors and modify
prepotent responses” (p.274). These abilities enable individuals “to fine tune their behavior
across a variety of domains” (p.274). It has been documented that deficits in depression
behaviorally across working memory/continuous performance and response inhibition are
present. “Neuroimaging studies also show that, compared to healthy patients, depressed patients
show altered activation of cognitive function circuitry across a range of tasks that tap into
working memory/continuous performance, planning, and inhibition” (Gyruk, 2016, p.274).
In the iSPOT-D trial, neuroimaging data was collected before and after randomized
treatment with three commonly prescribed antidepressants: escitalopram, sertraline, and
venlafaxine-extended release. Gyruk et al. (2016) performed MRI data analyses of patients
included in the iSPOT-D study and focused on 80 previously nonmedicated participants with
MDD and compared to 34 age, sex, and education matched healthy controls. Gyruk et al.
hypothesized that “neural activation, as assessed by functional MRI scans during 1 or all 3
cognitive task probes (response inhibition [Go/NoGo task], selective attention [oddball task], and
working memory updating [n-back continuous performance task]) in medication-free
pretreatment in depressed patients would predict antidepressant outcome” (p.275). Analyses also
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looked at if the neural signals would interact with specific medication type (SSRI, SRNI), and if
they will change with treatment as a function of remission.
A specific cognitive test called the Go/NoGo task assessed response inhibition. In this
assessment, it was shown that remitters to treatment were distinguished from nonremitters by
greater pretreatment right dorsolateral prefrontal cortex (DLPFC) activation. “MDD patients who
remitted were distinguished by relatively normal levels of DLPFC activation pretreatment, which
attenuated posttreatment” (Gyruk, 2016, p.279). Patients who did not reach remission showed
DLPFC hypoactivation at both pretreatment and posttreatment. A “failure to engage the DLPFC
region may be a general marker of nonresponsiveness to treatment” (p.279), as stated by Gyruk
et al. A region in the right inferior parietal cortex predicts HRSD remission differentially by
SSRIs compared to SNRIs. Regarding effects of medications, Gyruk et al. found that “remitters
specifically to SSRIs showed correspondingly normal levels of inferior parietal activation, which
also attenuated posttreatment, while nonremitters to SSRIs showed parietal hypoactivation. Thus,
SSRI and SNRI responders showed opposing patterns of activation in the parietal cortex”
(p.279).
Gyruk et al. (2016) aimed to identify neural predictors of outcomes of treatments and did
not compare active to placebo conditions. Further studies will need to be performed to expand
the array of antidepressant medication further, as only three medications were looked at. This
study also had a relatively small sample size and future studies should be performed to assess in
a larger sample group.
Brain Derived Neurotrophic Factor (BDNF)
Begni, Riva, and Cattaneo (2016) defined neurotrophins as “a family of proteins that
promote the growth, survival and differentiation of neurons” (p.123). In 1988, it was found that
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neuronal cells can secrete survival factors, neurotrophins, which promoted detailed studies. They
were “shown to regulate the growth, maintenance and apoptosis of neurons in both the central
nervous system (CNS) and the peripheral nervous system (PNS)” (Begni, 2016, p.123). There
are four main neurotrophins that are found in mammals, including nerve growth factor (NGF),
brain-derived neurotrophic factor, neurotrophin 3 and neurotrophin 4. Begni et al. performed a
review of BDNF and its involvement with pathological conditions.
The BDNF gene, as proposed by Begni et al. (2016), was found to be very complex. It
consists of multiple 5’-non-coding exons and one coding exon at the 3’ end. Certain exons were
found to be mostly brain specific, whereas others were expressed in the brain and non-neuronal
tissues. Ide et al. (2015) stated that “BDNF is highly expressed in the cortex, hippocampus,
limbic structures, cerebellum, and the olfactory bulb” (p.120). Functional roles have been
identified for different transcripts of BDNF, such as “alterations of hippocampus-prefrontal
cortex circuitry as well as deficits of γ-aminobutyric acid (GABA)-ergic interneurons in the
prefrontal cortex” (Begni, 2016, p.124). Of most importance, an alteration of certain BDNF
transcripts has been reported in several psychiatric disorders.
BDNF is the most common neurotrophin (Yang et al., 2016) and when secreted, binds to
certain receptors and initiates a series of downstream signaling cascades. This leads to the
prevention of programmed cell death and neuronal differentiation. Neurogenesis and
neuroplasticity are key mechanisms involved in memory and learning, and if this is disrupted,
can contribute to severe pathological conditions. BDNF plays a crucial role in brain development
and brain plasticity and decreased levels or impaired signaling can offer detrimental effects
(Begni et al., 2016).
BDNF as a Target for Treatment Intervention
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BDNF has been proven to be low in patients with MDD, however, it is still unclear the
exact mechanism behind how it works. Wolkowitz et al. (2011) aimed to “determine whether
serum BDNF levels are low in un-medicated depressed subjects compared to matched healthy
controls, whether serum BDNF levels increase in response to antidepressant treatment, and
whether baseline serum BDNF levels and treatment-associated changes in serum BDNF levels
are related to concurrent depression ratings” (p.1624).
Thirty subjects were included in this study that had unipolar MDD. The 17-item
Hamilton Depression Rating Scale (HDRS-17) was used to assess the severity of depression at
baseline and at the end of week 8 of antidepressant treatment. The average baseline of this score
was 26.1 ± 8.3. The depressed patients were divided into two separate studies and data was
pooled to increase statistical power. The first study involved escitalopram, while the other study
looked at sertraline, both SSRIs. There were 15 male patients treated in the escitalopram group
for 8 weeks in a single-blind, fixed-order, within-subject cross-over manner. In the second group,
14 depressed patients (9 female, 5 male) were prescribed sertraline in an open-label manner. Two
of these subjects dropped out and two did not have complete sets of data. The serum BDNF
levels were measured at baseline for all subjects and after 8 weeks of treatment for the depressed
patients.
The pre-treatment BDNF serum levels were significantly lower in the 29 depressed
subjects versus healthy controls, 14.88 ± 5.41 vs. 20.91 ±7.07, respectively. The HDRS-17
ratings (baseline =26.1 ± 8.3, week 8=13.2 ± 8.9) significantly improved with antidepressant
treatment, as well as serum BDNF levels (15.07 ± 5.41 at pre-treatment to 18.75 ± 6.97 at week
8).
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Many studies have already examined serum BDNF levels in un-medicated patients with
MDD, and nearly all of them have found decreased levels compared to controls. Wolkowitz et al.
(2011) results support these previous findings, as well as an increase of BDNF levels over the
course of antidepressant treatment. The study also found that subjects with initially higher serum
BDNF levels showed a larger antidepressant response to sertraline and escitalopram after 8
weeks of treatment.
According to Matrisciano et al. (2009), BDNF is a neurotrophin that has recently been
implicated in the pathophysiology of depression and the activity of antidepressant drugs. It
regulates neuronal function across life span and “affects neuronal outgrowth, synaptic
connectivity, and neuronal repair” (p.247). “Patients with MDD showed lower serum BDNF
levels, which negatively correlated with depression rating scores. The effect on BDNF appears to
be variable depending on the brain region, the cell type, length of treatment and the
pharmacological characteristic of the drug” (Matrisciano, 2009, p.248). Matrisciano et al. aimed
to compare serum BDNF levels in depressed patients versus healthy controls, test the action of
three antidepressant medications (sertraline, escitalopram, and venlafaxine) on serum BDNF
levels after 5 weeks and 6 months of treatment, and test the association between BDNF serum
levels and depression rating scores after treatment.
In this study, 21 subjects (11 males and 10 females) who met diagnostic criteria for MDD
and 20 normal controls (9 males and 11 females) were included. The patients were randomly
assigned to sertraline, venlafaxine, and escitalopram treatment for 6 months. At the beginning of
the trial, blood samples were collected, as well as after 5 weeks and 6 months of treatment. The
serum BDNF protein content was measured by ELISA using a commercially available kit. The
severity of depression was assessed using the HRSD and severity was defined as remission ≤7,
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mild depression between 7 and 17, and moderate-severe depression ≥17. This assessment was
done at baseline, 5 weeks, and 6 months.
There were 7 patients that were assigned to each of the three medications. The mean ±
SD of the baseline BDNF serum levels were: sertraline (29.4 ± 12.6), venlafaxine (32.3 ± 14.0),
and escitalopram (44.4 ± 16.4). The control group’s baseline BDNF score was 64.1 ± 13.1. The
BDNF levels at 5 weeks were: sertraline (50.6 ± 14.2), venlafaxine (29.1 ± 16.3), and
escitalopram (38.6 ± 14.4). The BDNF levels at 6 months were: sertraline (52.3 ± 12.7),
venlafaxine (54.9 ± 12.2), and escitalopram (41.6 ± 14.1). The HRSD scores at baseline were:
sertraline (19 ± 5.3), venlafaxine (19.4 ± 4.5), and escitalopram (14.3 ± 5.9). With sertraline,
HRSD scores showed 57.1 % of patients had reached remission at 5 weeks and 100% of patients
at 6 months. With venlafaxine, 85.7% reached remission at 5 weeks and 100% at 6 months. With
escitalopram, 100% reached remission at both 5 weeks and 6 months.
Matrisciano et al. (2009) showed that BDNF levels were lower in depressed patients
versus healthy controls. A significant increase in BDNF serum levels after 5 weeks of treatment
with sertraline and after 6 months of sertraline and venlafaxine were present. All three
antidepressants were effective in relieving depression symptoms after 5 weeks and 6 months,
despite their different effects on serum BDNF levels.
The relatively small sample size in this study performed by Matrisciano et al. (2009) may
have limited its ability to determine meaningful differences. The symptom assessments were
only done by HRSD scores and this may have caused missed components in the depressive
syndrome. Also, the difference in age between the controls and the study group may have
affected the baseline BDNF levels. The younger age of the healthy controls may explain the
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higher BDNF levels at baseline, however, the role of aging on neurotrophic factors needs more
research before assuming this limitation.
According to Ristevska-Dimitrovska et al. (2013), depressive disorder is not completely
understood, however, there is evidence that “complex interactions of biological, genetic,
psychosocial, and environmental factors” (p.123) are present. “BDNF involvement in depression
has been a focus of intensive research for the last decade” (Ristevska-Dimitrovska, 2013, p.123).
It is detectable in blood, although its concentration in brain tissue is much higher. It may pass the
blood-brain barrier and indicates that serum BDNF levels may reflect the BDNF levels in the
brain. In comparison to research found in Matrisciano et al. (2009), Ristevska-Dimitrovska et al.
stated that BDNF levels in untreated patients with MDD have been shown to be reduced and are
in negative correlation with depression severity. Ristevska-Dimitrovska et al. aimed to “test the
effect of antidepressant treatment on serum BDNF levels in patients with a depressive episode”
(p.124). Two separate studies in Macedonia and Bulgaria were conducted and results were
assessed both individually and integrated.
In the Macedonian study, 23 patients (11 female, 12 male) that were diagnosed with a
first depressive episode were included. The severity of depression was assessed with the HDRS.
The control group consisted of 23 subjects that were age and sex matched. Patients were then
treated with sertraline, paroxetine, or venlafaxine for approximately 8 weeks. In the Bulgarian
study, 10 female patients with depression and 10 control subjects were included. In both studies,
blood samples were collected at baseline and after patients achieved remission, however, the
HDRS scores were only assessed in the Macedonian study.
In the Macedonian study, the following were the results of serum BDNF levels and
HDRS scores: BDNF pre-treatment (13.15 ± 6.75), BDNF post-treatment (24.73 ± 11.80),
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BDNF controls (25.95 ± 9.17), HDRS before treatment (28.52 ± 4.02), and HDRS after
treatment (7.04 ± 3.15). In the Bulgarian study, the results were: BDNF pre-treatment (26.84 ±
8.66), BDNF post-treatment (30.33 ± 9.25), and BDNF controls (25.04 ± 2.88). In the integrated
study, the results were: BDNF pre-treatment (17.30 ± 9.66), BDNF post-treatment (26.43 ±
11.25), and BDNF controls (25.68 ± 7.76).
In the Bulgarian sample, no statistically significant difference between serum BDNF
levels of depressed patients before and after treatment was found. Limitations to these results
could include the small sample size and the short duration of treatment course, as it was only
three weeks. In the Macedonian sample, there was a statistically significant difference between
serum BDNF levels in depressed patients at baseline, after treatment, and compared to healthy
controls. Antidepressant treatment increased serum BDNF levels in depressed patients that were
close to the healthy controls. In the integrated study, lower levels of BDNF were shown while
depressive symptoms were evident.
There was no statistically significant difference in BDNF levels between patients treated
with sertraline, paroxetine, or venlafaxine. Again, the small sample size is an important
limitation in this study. Another question arises on if serum BDNF levels do reflect levels of
BDNF in the brain. These limitations need to be considered, however, there is promising
evidence showing that BDNF may be an important feature of depressive disorder.
Cattaneo et al. (2010) stated that BDNF is known to play a crucial role “in the
neurodevelopment and the maintenance of adult brain homeostasis through regulation of
neurogenesis and neuronal plasticity” (p.103). There have been several studies that have
suggested an involvement of BDNF in the pathogenesis of major depression(MD). Metaanalyses have shown that BDNF in the serum was significantly decreased in drug-free patients
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with depression. It has also been shown that pharmacological and non-pharmacological
antidepressant treatments have induced normalization of BDNF blood deficits (Cattaneo et al.,
2013).
In comparison to Ristevska-Dimitrovska et al. (2013), Cattaneo et al. (2010) stated that
blood BDNF may derive from brain production and crossing the blood brain barrier, but it can
also be synthesized from different peripheral cells, “such as vascular endothelial cells, smooth
muscle cells, in addition to leukocytes” (p.104). Leukocytes have been shown to express genes
that encode neurotransmitter receptors and transporters, stress mediators, cytokines, hormones,
and growth factors. This has proved similar to brain cells and may be a useful model to study
mental illness. “Altered mRNA levels of genes encoding dopamine and glucocorticoid receptors,
the serotonin transporter, the transcription factor cAMP response element-binding protein
(CREB), and other genes involved in calcium signaling have been found in the peripheral
leukocytes of MD patients (Cattaneo, 2010, p.104).
Cattaneo et al. (2010) evaluated whether leukocyte BDNF gene expression was altered in
MD patients compared to control subjects. They also aimed to observe the changes in BDNF
gene expression during 12-week treatment with escitalopram and assess whether changes in
BDNF mRNA levels would correlate with BDNF protein serum content. Twenty-one patients
(17 females, 4 males), age 18-65 years, were included in this study, as well as a control group of
16 females and 7 males. The patients were treated with escitalopram over a 3-month period. The
Montgomery-Asberg Depression Rating Scale (MADRS) was used to assess illness severity at
baseline, and at weeks 8 and 12 of treatment. Blood BDNF samples were collected at the same
time of clinical evaluation.
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BDNF serum and mRNA leukocyte levels in controls and in depressed patients were
expressed as mean ± standard deviation. The serum BDNF values for control, baseline, after 8week treatment, and after 12-week treatment are 40.92 ± 10.05, 30.58 ± 9.13, 31.92 ± 8.58, and
41.38 ± 10.49, respectively. The mRNA leukocyte levels for control, baseline, after 8-week
treatment, and after 12-week treatment are 1.01 ± 0.22, 0.48 ± 0.18, 0.57 ± 0.25, and 1.02 ± 0.15,
respectively. The BDNF serum and mRNA leukocyte levels showed a significant decrease in the
MD patients compared to controls, as well as increased the level past baseline with escitalopram
treatment. The MADRS scores at baseline, week 8, and week 12, showed the following values,
21.42 ± 3.17, 11.23 ± 7.07, and 7.23 ± 5.15, respectively. The drug treatment improved
symptoms and significantly decreased MADRS scores. There was no correlation observed
between baseline BDNF levels in the serum and leukocytes and severity of illness, as measured
by MADRS.
Ghosh, Gupta, R., Bhatia, Tripathi, and Gupta (2015) state that increases in BDNF in the
hippocampus of the brain have been reported in multiple human and preclinical studies,
however, the mechanistic and therapeutic significance of this is still uncertain. With the
emergence of many newer antidepressant medications, it is even more difficult to select an
optimum therapy. Ghosh et al. states that there have been recent studies showing that SNRIs,
which enhance norepinephrine and serotonin, may result in higher response and remission rates
than SSRIs, which only increase serotonin. This randomized, open label, prospective,
observational study was carried out to “compare and correlate the clinical efficacy, safety
profiles, and plasma BDNF levels in patients” (Ghosh, 2015, p.38) with MDD treated with
fluoxetine, a SSRI, and desvenlafaxine, a major active metabolite of the SNRI venlafaxine.
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In this study, 60 patients aged 18-60 years with a diagnosis of moderate to severe MDD
were included. The Hamilton’s 21 item depression rating scale (HAM-D) was used to clinically
evaluate depression at baseline, 6 weeks, and 12 weeks, and BDNF plasma samples were
obtained at baseline and at week 12 of treatment. The patients were than divided into two groups
and randomly assigned to either treatment with fluoxetine or desvenlafaxine.
In the fluoxetine group, there were 19 patients with moderate depression (HAM-D score
15-20) and 11 with severe depression (HAM-D score >20). The mean HAM-D score at baseline
was 19 ± 4.09, which was reduced to 12.2 ± 4.58 at six weeks post treatment, and further
reduced to 9.24 ± 3.98 at 12 weeks post treatment. The mean BDNF level at the start of
treatment was 775.32 ± 30.38 and increased to 850.3 ± 24.92 at 12 weeks post treatment.
In the desvenlafaxine group, there were 22 patients with moderate depression and 8 with
severe depression. The mean HAM-D score at baseline was 18 ± 3.75, which reduced to 13.5 ±
3.86 at 6 weeks and further reduced to 10 ± 3.75 at 12 weeks. The mean BDNF level at the start
of treatment was 760.5 ± 28.53 which increased to 845.8 ± 32.82 at 12 weeks post treatment.
Ghosh et al. (2015) found that plasma BDNF levels increased in MDD patients after 12-week
treatment with both desvenlafaxine and fluoxetine.
Kurita et al. (2012) stated that there are two groups that exist among MDD patients: “a
group that responds to treatment (the responder group) and a group that is refractory to treatment
(the non-responder group)” (Kurita, 2012, p.1). This naturalistic study examined BDNF levels in
patients who reached remission and non-responder groups. The changes in plasma BDNF were
compared among these two groups.
As with Cattaneo et al. (2010), the MADRS was used to assess the severity of depression.
A score of at least 18 represented inclusion criteria. Non-responders were defined as those
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refractory to treatment, showing a <50% reduction in MADRS score from the depressive
symptom stage. Patients in remission were defined as those with an improvement of symptoms
and a MADRS score ≤ 8 after treatment. From a total of 110 patients, 79 were selected for
inclusion based on the severity of illness. The patients were categorized into two groups: a
remission group and non-responder group based on definitions described earlier. Thirty-one
patients were excluded because they either ceased treatment within three months, received
intermittent treatment, or showed response with incomplete remission. 38 subjects in the
remission group (19 men and 19 women) and 10 subjects in the non-responder group (3 men and
7 women) were included in the final analysis.
A wide range of antidepressants were administered to each group and included
amitriptyline, clomipramine, fluvoxamine, imipramine, maprotiline, milnacipran, paroxetine,
sertraline, sulpiride, trazadone, amoxapine, aripiprazole. The plasma BDNF levels were
measured at the depressive syndrome stage, response stage, and remission stage. The period from
the depressive syndrome stage to the response stage was 7.2 ± 8.6 weeks, and the period from the
depressive syndrome stage to the remission stage was 12.3 ± 12.6 weeks. The treatment period
that was selected for the non-responder group and remission group was 8 weeks. The periodmatched depressive symptom/remission time frame was approximately 12 weeks in the nonresponder group.
In the remission group, the MADRS score before treatment and at time of response and
remission after treatment were 33.7 ± 8.9, 10.9 ± 5.9, and 5.0 ± 2.4, respectively. The plasma
BDNF levels in the depressive syndrome, response, and remission stages were 1,827 ± 1,340,
2,402 ± 1,610, and 3,158 ± 2,033, respectively.
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In the non-responder group, the MADRS score at the depressive syndrome stage, and at 8
and 12 weeks after treatment were 35.1 ± 6.5, 25.8 ± 7.7, and 35.2 ± 11.4, respectively. The
plasma BDNF levels in the syndrome, and 8 and 12 weeks after treatment were 2,932 ± 2,373,
2,117 ± 2,042, and 1,619 ± 1,698, respectively.
In the remission group, the MADRS scores reduced significantly over the course of
treatment and the BDNF levels increased significantly with clinical improvement. Patients in the
non-responder group did not show much difference in the MADRS scores, however, the plasma
BDNF levels were still significantly decreased during the syndrome’s 8-12-week period and may
prove that it is “an important biomarker for the prognosis of MDD” (Kurita, 2010, p.5).
The disagreement of the period of remission in responders and non-responders is a
limitation of naturalistic studies. The other limitation was the variation in drug treatment that was
used between the two groups, as well as the amount of medications used. The effects of
antidepressants on BDNF levels appear to not be uniform in this study.
DISCUSSION
It is clear that MDD is a very complex disorder. There are many pathways involved in the
pathophysiology and this makes it difficult to find treatment options that will work for patients.
There have been newer hypotheses in the pathophysiology of MDD that have been highlighted in
the last couple of years. The literature has shown that BDNF and cognitive-emotional biomarkers
may be important factors in this disorder. The following section is a discussion of the review of
literature, focusing on how BDNF and cognitive-emotional biomarkers are involved in MDD and
their role in predicting treatment success and remission.
In adults with MDD, does BDNF play a role in the pathophysiology of MDD?
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Both Cai et al. (2015) and Rot et al. (2009) stated that the pathophysiology of MDD has
been mainly based on the monoamine-deficiency hypothesis. This hypothesis focuses on
decreased levels of serotonin, norepinephrine, and dopamine being the cause of MDD. However,
there are antidepressant medications to acutely increase all of these neurotransmitters in the
brain, and there is only a small number of patients that actually reach remission. This suggests
that there is more to the pathogenesis of depression.
The review performed by Cai et al. (2015) found that the many different hypotheses
behind the pathogenesis of MDD are “complimentary and mutually linked” (p.70). Genetic and
environmental factors, including stress, seem to “initiate a cascade of neurobiological changes
that disrupt a dynamic system” (Cai et al., 2015). Glutamate dysfunction, an increase in
inflammatory cytokines, an imbalance of the HPA axis, and decreased monoamines all seem to
lead to a decrease in BDNF and synaptic plasticity, as well as an increase in apoptosis. These
two things seem to be the common pathway in depression, as reported by Cai et al.
Rot et al. (2009) focused on the genetic and environmental factors that Cai et al. (2015)
found to initiate neurobiological changes with MDD. Rot et al. found that genes help control
neurotransmitter metabolism and environmental stressors can change the speed of neuronal
signaling, and interruptions of both of these processes can lead to depression. This review also
found that a polymorphism of BDNF may increase depression vulnerability.
Begni et al. (2016) stated that neurotrophins, such as BDNF, regulate growth and
apoptosis of neurons in the CNS and PNS. If BDNF levels are decreased, an impairment of brain
development and brain plasticity will occur. Yang et al. (2016) stated that neurogenesis and
neuroplasticity are mechanisms involved in memory and learning, and if disrupted as with
decreased BDNF levels, MDD may occur. Begni et al. also stated that decreased levels of BDNF
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“may be one of the consequences of a genetic background of vulnerability, as well as of
exposure to adverse environmental events” (p.130). In comparison to Cai et al. (2015), Begni et
al. stated that “inflammation, neurotransmitter dysfunction, and altered HPA axis function, may
affect BDNF function, leading to deficits in synaptic and neuronal plasticity and enhanced
vulnerability to developing several neuropsychiatric disorders” (p.130).
Begni et al. (2016) stated that in 2006, the neurotrophin hypothesis of depression was
proposed, which suggested that “a deficiency in neurotrophin levels may contribute to cell
atrophy in selected brain areas of MDD patients” (p.129). Studies have established the ability of
BDNF to promote antidepressant effects in rats after infusion into the hippocampus or lateral
ventricles of the brain. A number of human postmortem studies have demonstrated lower BDNF
expression in MDD patients, as well as decreased signaling in the hippocampus and prefrontal
cortex. Yang et al. (2016) stated that neuroimaging of depressed adult patients demonstrated the
“involvement of decreased neurogenesis in the underlying pathophysiology of MDD” (p.72).
Caldieraro et al. (2017) reported that since the introduction of the neurotrophin hypothesis,
BDNF “has become one of the most widely-studied biomarkers” (p.46) of MDD and the
mechanism behind it is currently considered “one of the central elements in the
pathophysiology” (p.46) of depression. It is obvious that other studies share the same thought.
In treatment of adults with MDD, do cognitive biomarkers predict the efficacy and
outcome of treatment and remission?
“Cognitive deficits are considered as key symptoms of clinical depression that are
associated both with suboptimal response to antidepressants and reduced remission rates”
(Castellano, 2016, p.1295). In the study performed by Castellano et al., it was found that both
SSRIs and SNRIs reduced affective symptoms in MDD patients after 12 weeks of treatment, as
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well as improved cognitive function, however the improvements were independent from each
other. This suggests that affective and cognitive symptoms should be considered as different
pathological dimensions of MDD. Castellano et al. stated that “imbalance or deficiency in
serotoninergic and/or noradrenergic systems has been found to contribute to cognitive deficits”
(p.1296), and this may help guide the efficacy of certain medications in the treatment of patients
with MDD.
The analysis performed by Etkin et al. (2015) showed that participants were categorized
into two subgroups based on their cognitive and emotional test performance. The ‘intact’
subgroup was “composed of approximately ¾ of the MDD participants who performed on
average within the healthy range” (p.1336). The ‘impaired’ subgroup included “participants with
a test performance well below the healthy norm for 11 of the 13 aspects of function” (p.1336). It
was shown that the impaired subgroup was older, less educated, and had greater depressive
severity than the intact group. The intact group had a better overall response to treatment.
Etkin et al. (2015) found that “response with antidepressant medication can be reliably
predicted for outpatients with MDD by their pretreatment performance on a standardized test
battery of cognitive and emotional function”, however, “this prediction was only evident in a
subgroup of participants who had impaired performance across these tests relative to other
depressed participants and healthy controls” (p.1340). Patients in the impaired subgroup were
shown to have worse treatment response, however, this outcome was able to be predicted and
may offer a valuable tool in predicting treatment outcome.
The iSPOT-D trial that was analyzed by Etkin et al. (2015) was also analyzed by Gyruk
et al. (2016), however Gyruk et al. analyzed MRI data performed during this trial. As stated
earlier, the results showed that activation in the frontoparietal region of the brain predicted
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remission with antidepressant treatment, particularly SSRIs. In comparison to Etkin et al., Gyruk
et al. found that patients who reached remission were younger in age, however, their years of
education did not make a difference with Gyruk et al.
It is clear that there are a few different cognitive biomarkers that have proven to predict
the outcome of certain antidepressants. This may offer a new development in the treatment of
MDD, however, these three studies analyzed different things and more studies with larger
number of subjects will need to be performed.
In treatment of adults with MDD, does BDNF predict the efficacy and outcome of
treatment and remission?
The neurotrophin hypothesis of depression theorized that “certain central BDNF
deficiencies underlie depression, and that antidepressants work via restoration of central BDNF
activity” (Wolkowitz et al., 2011, p.1623). There have been several studies that have found low
serum BDNF levels in un-medicated depressed patients, and that these levels increase with
antidepressant treatment. The question arises on if BDNF has a role in the etiology of depression
or if it has more of a role in the mechanism of action of antidepressants (Wolkowitz et al., 2011).
Wolkowitz et al. (2011) found supporting results with low BDNF in depressed patients.
The study also found that BDNF levels increased over the course of antidepressant treatment
with sertraline and escitalopram. Wolkowitz et al. stated that there is greater evidence to support
that BDNF may be a target of antidepressant action versus in the development of depression
itself, as BDNF signaling is necessary for antidepressant effects to occur.
The study performed by Wolkowitz et al. (2011) also found that patients with initially
higher serum BDNF levels showed a larger antidepressant response to sertraline and
escitalopram. Patients with higher pre-treatment serum BDNF levels may be either less
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depressed, or may already be nearing remission, and this may predict an enhanced response to
SSRI antidepressants, however, larger studies need to be replicated before confirmation of these
findings can occur.
In comparison with results found by Wolkowitz et al. (2011), Matrisciano et al. (2009)
also found that BDNF levels were lower in depressed patients. In this study, an increase of
BDNF levels after treatment with either sertraline or venlafaxine occurred, however,
escitalopram did not increase levels. It is interesting to note that in the study performed by
Wolkowitz et al., escitalopram increased BDNF levels, in contrast to findings by Matrisciano et
al. This may be due to the pooling of data that occurred and results may have been different if
they were divided.
The study performed by Matrisciano et al. (2009) also found an important difference in
the effects of BDNF at different time intervals with the antidepressant treatments. The different
timing of BDNF increase could be due to the different mechanism of action of these medications
and the contribution to the multitude of BDNF production. There was also a “significant
association between the increase in BDNF serum levels and the decrease in HRSD scores at
endpoint, indicating that a higher percentage increase of BDNF serum levels correspond to a
clinical remission from depressive symptoms” (Matrisciano, 2009, p.252).
A study performed by Ristevska-Dimitrovska et al. (2013) again found similar results to
Wolkowitz et al. (2011) and Matrisciano et al. (2009), in which low levels of BDNF were shown
with MDD patients. One part of the study by Ristevska-Dimitrovska et al. found that BDNF
levels increased after treatment with sertraline, paroxetine, and venlafaxine. These results again
correlate with previous findings of other studies with sertraline and venlafaxine. As patient’s
symptoms improved with antidepressant treatment, the BDNF levels increased significantly.
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Ristevska-Dimitrovska et al. shows that chronic antidepressant treatment can significantly
increase BDNF levels in patients with depressive disorder when patients achieve remission. “A
low serum BDNF level may be an important feature of depression” (Ristevska-Dimitrovska,
2013, p.126).
Cattaneo et al. (2010) took a different approach in his study and evaluated leukocyte
BDNF. The study compared this to serum BDNF, as well as the effects of treatment with
escitalopram. The results showed decreased serum and leukocyte BDNF levels in MD patients,
as well as an increase in BDNF levels after treatment with escitalopram.
According to a meta-analysis performed by Sen, Duman, and Sanacora (2008), there is an
overwhelming amount of evidence that shows reduced serum BDNF levels in depressed patients
and that these levels normalize after antidepressant treatment. Cattaneo et al. (2010) states this
may suggest “that BDNF serum fluctuations may reflect neurotrophic disturbances in limbic
regions and restoration processes induced by antidepressant treatment (p.106). Cattaneo et al.
found new evidence that BDNF mRNA levels in leukocytes were also reduced in MD patients
and were increased to levels similar in controls during treatment with escitalopram. It was also
found that an increase in these levels was associated with amelioration of symptoms.
A limitation to Cattaneo et al. (2010) focuses on the fact that “BDNF blood alterations
are not specific to MD” (p.107). It has been found that other psychiatric disorders, including
bipolar disorder, schizophrenia, and eating disorders, also demonstrate this finding. It is not
considered a marker of illness. However, it does connect a common pathophysiological
mechanism to these disorders, in which BDNF is linked to deregulation of synaptic plasticity. It
“may also provide some insight into the high rates of comorbidity that exist between many of the
disorders” (Cattaneo, 2010, p.107).
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Another limitation to Cattaneo et al. (2010), is that a differentiation cannot be made of
whether a BDNF increase observed during escitalopram treatment is due to the medication or
from an improvement of depressive symptoms. Ristevska-Dimitrovska et al. (2013), found an
increase with sertraline, paroxetine, and venlafaxine and Matrisciano et al. (2009) found an
increase with sertraline, escitalopram, and venlafaxine. All three studies demonstrated an
improvement of depressive symptoms, however, two different methods were utilized in assessing
those scores. A larger study comparing these three medications will need to be performed to
accurately differentiate the cause of the increase in BDNF.
Ghosh et al. (2015) compared the efficacy, safety, and plasma BDNF levels of MDD
patients treated with fluoxetine and desvenlafaxine. This study found that plasma BDNF levels
increased after 12-week treatment with both of these medications. In comparison with
Matrisciano et al. (2009), the efficacy and safety profile of desvenlafaxine and fluoxetine is
comparable in patients with MDD.
Both antidepressant medications significantly increased BDNF levels, however the small
sample size in this study severely limits the results. In previous studies in this category
(Cattaneo, 2010; Matrisciano, 2009; Ristevska-Dimitrovska, 2013; Wolkowitz, 2011), the serum
BDNF levels have been measured, in contrast to Ghosh et al. who measured the plasma BDNF
levels. Some studies have mentioned that plasma BDNF may be a better reflection of brain
BDNF levels, but more studies are needed to prove this observation.
Ghosh et al. (2015) also mentions that there were 26 patients that responded to treatment
with fluoxetine (4 non-responders) and 27 who responded to desvenlafaxine (3 non-responders).
The responders to treatment had higher pre-treatment BDNF levels than non-responders, which
compares to research found with Wolkowitz et al. (2011) in which higher BDNF levels, initially,
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showed a larger antidepressant response. The post treatment values were greater in the responder
groups of both medications as compared to the non-responder group.
Kurita et al. (2010) aimed to investigate responders and non-responders more thoroughly.
This study compared plasma BDNF levels in patients that reached remission and those that did
not. Kurita et al. found that the plasma BDNF levels in the non-responder group decreased over
time. He stated that it has been shown that BDNF levels will increase by antidepressants,
environmental enrichment, and modest exercise, and are decreased by stressful events. This
information suggests “that the ability of stress to decrease BDNF levels may be greater than the
ability of antidepressants to increase BDNF levels” (Kurita, 2010, p.6). Also, if a person looks at
the levels of BDNF in the remission versus non-responder group, it can be noted that they are
higher in the non-responder group as well as in the depressive syndrome stage, which is in
contrast to research found with Wolkowitz et al. (2011) and Ghosh et al. (2015). “High plasma
BDNF levels during the depressive syndrome stage may be indicative of treatment-resistant
MDD patients. Thus, plasma BDNF levels may help the clinician to predict clinical outcome. In
particular, if plasma BDNF levels decrease or are unchanged in an individual with regularly
measured plasma BDNF, the clinician may need to reevaluate treatment strategy (Kurita, 2010,
p.6).
Overall, the review of literature in this subject showed that BDNF levels were decreased
in patients with MDD. It also showed that these BDNF levels increase over time with
antidepressant treatment with certain medications. These results may offer a tremendous gain in
the treatment of adults with MDD and may finally be able to help find treatment options for
patients that will work.
APPLICABILITY TO CLINICAL PRACTICE
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In clinical practice, MDD is a disease process that will be encountered many times in a
provider’s career. Whether it is a primary care provider or an emergency room provider, it is a
disease process that is seen on a daily basis, both with treatment strategies and as a comorbid
condition. It is a disorder that is growing in frequency, however, there are many flaws in the
treatment of MDD, as only a small percentage of patients find a treatment option that offers
remission. In some cases, it takes years to find a medication option that works for a patient. This
can be both devastating and frustrating to both the patient and the provider. It is still unclear of
how this disease process works but new hypotheses in the pathophysiology of MDD have
become available that may help alleviate the stress of finding treatment options that work.
My research found that both cognitive biomarkers and BDNF may be the key to finding
treatment options for patients with MDD faster and more effectively. Based on cognitive and
emotional tests performed before antidepressant treatment, studies were able to predict treatment
response to certain SSRI’s and SNRI’s and this may help in clinical practice. It was also found
that BDNF is decreased in patients with MDD and certain antidepressants are able to increase
this level. Some studies showed that a higher BDNF level showed a larger antidepressant
response.
If providers are able to predict whether certain medications will work before starting
them, this can alleviate a large amount of stress and frustration. Cognitive and emotional tests
performed prior to antidepressant treatment may be an option to predicting if a medication will
work. Also, measuring BDNF levels before and during the course of treatment may help
providers predict if antidepressant treatment will work much sooner than has previously been
possible. Although there is much more research to be done on these two biomarkers, they
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provide a good look into the future of MDD and are an exciting step in the right direction
towards successful treatment of this disorder.
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